Aquestive Therapeutics, Inc. · NASDAQ:AQST

Aquestive Therapeutics — Q1 2025 Earnings Presentation

9 slides from Aquestive Therapeutics's earnings presentation, May 12, 2025

  1. Slide 1: First Quarter 2025 Earnings Supplemental Materials

    Advancing medicines. Solving problems. Improving lives. September 2024 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. First Quarter 2025 Earnings Supplemental Materials May 12, 2025

  2. Slide 2: Disclaimer

    © 2025 Aquestive Therapeutics, Inc. 2 ® Disclaimer Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” o

  3. Slide 3: Q1 2025 earnings key messages

    3 Q1 2025 earnings key messages Anaphylm (epinephrine) Sublingual Film for severe allergic reactions, including anaphylaxis • NDA was submitted in Q1 2025; FDA Acceptance of the NDA expected in Q2 2025 • Pediatric clinical trial completed; Positive top-line results • Clinical program for Anaphylm is

  4. Slide 4: Film dosing option preference – Patients and HCPs

    4 Film dosing option preference – Patients and HCPs¹ 80% prefer a non-injection dosing method 95% are interested in a film-dosing option 95% believe a film-dosing option fills an unmet need in the epinephrine market 85% indicated they would Rx a film-dosing option PATIENTS AND CAREGIVERS HEALTHCARE

  5. Slide 5: Upcoming expected key milestones

    5 Upcoming expected key milestones AQST – 108 Libervant® Q1 2025 Q2 2025 Q3 2025 Q4 2025 AnaphlymTM NDA Submission Pediatric Study Completed Open IND Expected NDA Acceptance Potential Advisory Committee Meeting Potential ex-U.S. Approval Filings Potential licensee-led ex-U.S. Approval Filings

  6. Slide 6: Positioned to meet near-term milestones with projected cash runway into 2026

    6 Positioned to meet near-term milestones with projected cash runway into 2026 $89.9 $77.9 $93.0 $68.7 0 20 40 60 80 100 120 Q2 24 Q3 24 Q4 24 Q1 25 U S D ( M ill io n s ) Ending Cash Balance by Quarter

  7. Slide 7: Doses Shipped by Quarter

    7 41,097 36,863 33,458 47,953 46,241 45,328 42,516 34,418 43,818 43,032 27,392 0 10,000 20,000 30,000 40,000 50,000 60,000 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 D O S E S S H IP P E D ( 0 0 0 ’S ) QUARTER Doses Shipped by Quarter Manufacturing operations continue to gener

  8. Slide 8: 2025 guidance as of May 12, 2025

    8 2025 guidance as of May 12, 2025¹ 2025 Outlook • Total revenues of approximately $44-$50 million • Non-GAAP adjusted EBITDA loss of approximately $47-$51 million 1. Guidance was revised primarily due to the change in the regulatory status of Libervant pausing sales and marketing activities for the

  9. Slide 9: Thank You

    << Aquestive’ Thank You

Aquestive Therapeutics — Q1 2025 Earnings Presentation on 6ix